Leading the Way in Life Science Technologies

GEN Exclusives

More »

May 15, Vol. 33, No. 10

  • Columns

    • Crowdfunding Touches Down in Biotech
    • Alex Philippidis
    • A year has passed since President Barack Obama enacted a law intended to spark business growth by encouraging “crowdfunding” of startups Much of the law remains to be implemented, but that hasn’t stopped crowdfunding sites Poliwogg and Microryza from employing ... more »
    • Biotechs Need to Walk the Walk on Drug Value
    • Small- to mid-sized biotechnology companies must retool their R&D strategies to pay as much attention to how private and government insurers or “payers” will value their new drugs as is traditionally paid to making the medicines work, Ernst & Young ... more »
    • Softening the Blow from FOLFOX Treatment
    • Just as serendipity wrought the discoveries that Viagra did wonders for sexual dysfunction in men, and Dramamine treated travel sickness better than allergies, so too did it cause a seven-year-old Swedish drug developer to reposition the MRI contrast agent mangafodipir, ... more »
    • Highlights from AACR
    • At the 2013 AACR meeting, Stand Up to Cancer (SU2C) formally introduced its alliance with the St Baldrick’s Foundation and announced the newest SU2C research Dream Team, targeting pediatric cancers The Dream Team will receive a $145 million translational cancer ... more »
    • Advertorial: Agilent Technologies
    • Agilent Technologies (spun off from Hewlett Packard in 1999) maintains a clear focus on analytical measurement and has leveraged its considerable expertise in chemical analysis into the creation of a large portfolio of life science tools Agilent analytical systems, bioinformatics ... more »
  • Tutorials

    • Fluorescence Lifetime Assays
    • Graham Cotton
      Wayne Bowen, Ph.D.
    • Luminescence and fluorescence-based assay methods prevail in modern HTS Although invaluable as technologies, the problem of compound-related assay interferences such as quenching, auto-fluorescence, and light scattering becomes important The degree of interference experienced may depend on variables such as assay ... more »
    • Diversifying Your Antibody Portfolio
    • Thomas O. Kohl, Ph.D.
    • Today’s biopharmaceutical industry faces significant challenges identifying antibody reagents useful in the development of difficult therapeutic and/or diagnostic applications Target-specific antibodies, irrespective of clonality, are traditionally developed and produced in wild-type animals upon immunization with a specific antigen However, the ... more »